Myelodysplastic syndromes: The complexity of stem-cell diseases

Nature Reviews Cancer

Volumn 7, Issue 2, 2007, Pages 118-129

  Corey, Seth J ^a   Minden, Mark D ^b   Barber, Dwayne L ^b   Kantarjian, Hagop ^a   Wang, Jean C Y ^b   Schimmer, Aaron D ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; AMIFOSTINE; AZACITIDINE; CASPASE; CYTARABINE; CYTOKINE; DEPSIPEPTIDE; DOXORUBICIN; ETOPOSIDE; HISTONE DEACETYLASE INHIBITOR; INFLIXIMAB; LBH 589; LENALIDOMIDE; MGCD 0103; PENTOXIFYLLINE; TENIPOSIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; AGE DISTRIBUTION; ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; ATAXIA TELANGIECTASIA; BLACKFAN DIAMOND ANEMIA; BONE MARROW DISEASE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CELL DIFFERENTIATION; CELL STRUCTURE; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA; CYTOPENIA; DIFFERENTIAL DIAGNOSIS; DYSKERATOSIS CONGENITA; EPIGENETICS; FANCONI ANEMIA; GENE MUTATION; HEMATOPOIESIS; HUMAN; MALIGNANT TRANSFORMATION; MEDICAL EXAMINATION; MISMATCH REPAIR; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHUMAN; PANCYTOPENIA; PATHOLOGY; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REVIEW; SHWACHMAN SYNDROME; SOMATIC MUTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; MYELODYSPLASTIC SYNDROMES; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 33846515640     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc2047     Document Type: Review

References (114)

1. Aul, C., Giagounidis, A. & Germing, U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int. J. Hematol. 73, 405-410 (2001).
2. Komrokji, R. Myelodysplastic syndromes: a view from where the sun rises and where the sun sets. Leuk. Res. 30, 1067-1068. (2006).
3. Matsuda, A. et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 106, 2633-2640 (2005).
4. Maserati, E. et al. Familial myelodysplastic syndromes, monosomy 7/trisomy 8, and mutator effects. Cancer Genet. Cytogenet. 148, 155-158 (2004).
5. Minelli, A. et al. Familial partial monosomy 7 and myelodysplasia: different parental origin of the monosomy 7 suggests action of a mutator gene. Cancer Genet. Cytogenet. 124, 147-151 (2001).
6. Bennett, J. M. et al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51, 189-199 (1982). This 25 year old classification scheme remains popular and widely used.
7. Vardiman, J. W., Harris, N. L. & Brunning, R. D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100, 2292-2302 (2002). The newer international classification scheme for all haematological neoplasms remains similar to the FAB scheme, with a crucial change in the number of blasts that defines AML.
8. Greenberg, P. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079-2088 (1997).
9. Howe, R. B., Porwit-MacDonald, A., Wanat, R., Tehranchi, R. & Hellstrom-Lindberg, E. The WHO classification of MDS does make a difference. Blood 103, 3265-3270 (2004).
10. Malcovati, L. et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J. Clin. Oncol. 23, 7594-7603 (2005).
11. Fenaux, P. & Kelaidi, C. Treatment of the 5q-syndrome. Hematology Am. Soc. Hematol. Educ. Program 192-198 (2006).
12. Wang, J. C. & Dick, J. E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15, 494-501 (2005).
13. Wang, J. C. Y. et al. in Hematopoiesis - A developmental approach (Ed. Zon, L. I.) 99-118 (Oxford University Press, 2001).
14. Lapidot, T. et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 367, 645-648 (1994).
15. Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med. 3, 730-737 (1997).
16. Hope, K. J., Jin, L. & Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunol. 5, 738-743 (2004).
17. Juvonen, E., Aimolahti, A., Volin, L. & Ruutu, T. The prognostic value of in vitro cultures of erythroid and megakaryocyte progenitors in myelodysplastic syndromes. Leuk. Res. 23, 889-894 (1999).
18. Sato, T., Kim, S., Selleri, C., Young, N. S. & Maciejewski, J. P. Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome. Leukemia 12, 1187-1194 (1998).
19. Nilsson, L. et al. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 100, 259-267 (2002).
20. - cells from patients with del(5q) syndrome, with implications for the identity of the MDS stem cell.
21. Asano, H. et al. Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes. Blood 84, 588-594 (1994).
22. Claessens, Y. E. et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 99, 1594-1601 (2002).
23. Campioni, D. et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am. J. Pathol. 166, 557-563 (2005). TNF-related apoptosis probably has an important role in low-risk MDS, although this mechanism has not been validated by anti-TNF agents.
24. Benito, A. I. et al. NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors. Leuk. Res. 27, 425-436 (2003).
25. Thanopoulou, E. et al. Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood 103, 4285-4293 (2004).
26. Kerbauy, D. M., Lesnikov, V., Torok-Storb, B., Bryant, E. & Deeg, H. J. Engraftment of distinct clonal MDS-derived hematopoietic precursors in NOD/SCID-beta2-microglobulin-deficient mice after intramedullary transplantation of hematopoietic and stromal cells. Blood 104, 2202-2203 (2004). References 25 and 26 describe the successful engraftment of clonal MDS cells in a more immunodeficient strain of NOD/SCID mice.
27. Ito, M. et al. NOD/SCID/γ(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100, 3175-3182 (2002).
28. Shultz, L. D. et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477-6489 (2005).
29. Buonamici, S. et al. EVI1 induces myelodysplastic syndrome in mice. J. Clin. Invest. 114, 713-719 (2004). Although others have modelled high-risk MDS by engrafting primary cells in immunodeficient mouse strains, the mouse model described in this study mimics many of the features found in low-risk MDS.
30. Grisendi, S. et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 437, 147-153 (2005).
31. Lin, Y. W., Slape, C., Zhang, Z. & Aplan, P. D. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood 106, 287-295 (2005). This transgenic mouse model comes closest to reproducing the different stages of MDS progression.
32. Moody, J. L. & Jirik, F. R. Compound heterozygosity for Pten and SHIP augments T-dependent humoral immune responses and cytokine production by CD(4+) T cells. Immunology 112, 404-412 (2004).
33. Disperati, P. et al. Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology. Leuk. Res. 30, 233-239 (2006).
34. Kardos, G. et al. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 102, 1997-2003 (2003).
35. Dong, F. et al. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N. Engl. J. Med. 333, 487-493 (1995).
36. Taniguchi, T. & D'Andrea, A. D. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107, 4223-4233 (2006).
37. D'Andrea, A. D. & Grompe, M. The Fanconi anaemia/BRCA pathway. Nature Rev. Cancer 3, 23-34 (2003).
38. Liu, J. M. & Ellis, S. R. Ribosomes and marrow failure: coincidental association or molecular paradigm? Blood 107, 4583-4588 (2006).
39. Chiocchetti, A. et al. Interactions between RPS19, mutated in Diamond-Blackfan anemia, and the PIM-1 oncoprotein. Haematologica 90, 1453-1462 (2005).
40. Amaravadi, R. & Thompson, C. B. The survival kinases Akt and Pim as potential pharmacological targets. J. Clin. Invest. 115, 2618-2624 (2005).
41. Boocock, G. R. et al. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nature Genet. 33, 97-101 (2003).
42. Wessels, D. et al. The Shwachman-Bodian-Diamond syndrome gene encodes an RNA-binding protein that localizes to the pseudopod of Dictyostelium amoebae during chemotaxis. J. Cell Sci. 119, 370-379 (2006).
43. Stepanovic, V., Wessels, D., Goldman, F. D., Geiger, J. & Soll, D. R. The chemotaxis defect of Shwachman-Diamond Syndrome leukocytes. Cell Motil. Cytoskeleton 57, 158-174 (2004).
44. Horwitz, M. et al. Role of neutrophil elastase in bone marrow failure syndromes: molecular genetic revival of the chalone hypothesis. Curr. Opin. Hematol. 10, 49-54 (2003).
45. Ancliff, P. J. et al. Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood 108, 2182-2189 (2006).
46. Rosselli, F. Fanconi anaemia syndrome and apoptosis: state of the art. Apoptosis 3, 229-236 (1998).
47. Gazda, H. T. et al. Defective ribosomal protein gene expression alters transcription, translation, apoptosis and oncogenic pathways in Diamond-Blackfan anemia. Stem Cells 24, 2034-2044 (2006).
48. Papadaki, H. A. & Eliopoulos, G. D. The role of apoptosis in the pathophysiology of chronic neutropenias associated with bone marrow failure. Cell Cycle 2, 447-451 (2003).
49. Dror, Y. & Freedman, M. H. Shwachman-Diamond syndrome marrow cells show abnormally increased apoptosis mediated through the Fas pathway. Blood 97, 3011-3016 (2001).
50. Carlsson, G. et al. Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells. Blood 103, 3355-3361 (2004).
51. Ruggero, D. et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 299, 259-262 (2003).
52. Betti, C. J., Villalobos, M. J., Diaz, M. O. & Vaughan, A. T. Apoptotic triggers initiate translocations within the MLL gene involving the nonhomologous end joining repair system. Cancer Res. 61, 4550-4555 (2001).
53. Betti, C. J., Villalobos, M. J., Diaz, M. O. & Vaughan, A. T. Apoptotic stimuli initiate MLL-AF9 translocations that are transcribed in cells capable of division. Cancer Res. 63, 1377-1381 (2003).
54. Josting, A. et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J. Clin. Oncol. 21, 3440-3446 (2003).
55. Rivera, G. K., Pui, C. H., Santana, V. M., Pratt, C. B. & Crist, W. M. Epipodophyllotoxins in the treatment of childhood cancer. Cancer Chemother. Pharmacol. 34 (Suppl.), S89-S95 (1994).
56. Crump, M. et al. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21, 3066-3071 (2003).
57. Brown, J. R. et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J. Clin. Oncol. 23, 2208-2214 (2005).
58. Viniou, N. et al. Acute myeloid leukemia in a patient with ataxia-telangiectasia: a case report and review of the literature. Leukemia 15, 1668-1670 (2001).
59. Meyn, M. S. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin. Genet. 55, 289-304 (1999).
60. Meyer, S. et al. Spectrum and significance of variants and mutations in the Fanconi anaemia group G gene in children with sporadic acute myeloid leukaemia. Br. J. Haematol. 133, 284-292 (2006).
61. Xie, Y. et al. Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells. Br. J. Haematol. 111, 1057-1064 (2000).
62. Harada, H. et al. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103, 2316-2324 (2004).
63. Harada, H., Harada, Y., Tanaka, H., Kimura, A. & Inaba, T. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 101, 673-680 (2003).
64. Karran, P., Offman, J. & Bignami, M. Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie 85, 1149-1160 (2003).
65. Offman, J. et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 104, 822-828 (2004).
66. Olipitz, W. et al. Defective DNA-mismatch repair: a potential mediator of leukemogenic susceptibility in therapy-related myelodysplasia and leukemia. Genes Chromosomes Cancer 34, 243-248 (2002).
67. Allan, J. M. et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl Acad. Sci. USA 98, 11592-11597 (2001).
68. Felix, C. A. et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl Acad. Sci. USA 95, 13176-13181 (1998).
69. Zang, D. Y., Goodwin, R. G., Loken, M. R., Bryant, E. & Deeg, H. J. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 98, 3058-3065 (2001).
70. Reza, S. et al. Biologic characteristics of 164 patients with myelodysplastic syndromes. Leuk. Lymphoma 33, 281-287 (1999).
71. Schmidt, M. et al. Role of the CD95/CD95 ligand system in glucocorticoid-induced monocyte apoptosis. J. Immunol. 166, 1344-1351 (2001).
72. Tehranchi, R. et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 101, 1080-1086 (2003).
73. Allampallam, K. et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int. J. Hematol. 75, 289-297 (2002).
74. Tauro, S., Hepburn, M. D., Bowen, D. T. & Pippard, M. J. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes. Haematologica 86, 1038-1045 (2001).
75. Tauro, S., Hepburn, M. D., Peddie, C. M., Bowen, D. T. & Pippard, M. J. Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes. Leukemia 16, 785-790 (2002).
76. Kook, H. et al. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp. Hematol. 29, 1270-1277 (2001).
77. Tehranchi, R. et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 106, 247-253 (2005).
78. Albitar, M. et al. Myelodysplastic syndrome is not merely 'preleukemia'. Blood 100, 791-798 (2002).
79. Hellstrom-Lindberg, E. et al. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br. J. Haematol. 112, 714-726 (2001).
80. Boudard, D. et al. Expression and activity of caspases 1 and 3 in myelodysplastic syndromes. Leukemia 14, 2045-2051 (2000).
81. Parker, J. E. et al. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 96, 3932-3938 (2000).
82. Boudard, D. et al. Increased caspase-3 activity in refractory anemias: lack of evidence for Fas pathway implication. Leukemia 16, 2343-2345 (2002).
83. Claessens, Y. E. et al. Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD. Blood 105, 4035-4042 (2005). This study shows that the blockade of CD95 results in the correction of MDS-associated anaemia.
84. Shimazaki, K., Ohshima, K., Suzumiya, J., Kawasaki, C. & Kikuchi, M. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. Br. J. Haematol. 110, 584-590 (2000).
85. Shetty, V. et al. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood 96, 1388-1392 (2000).
86. Williams, G. T., Smith, C. A., Spooncer, E., Dexter, T. M. & Taylor, D. R. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 343, 76-79 (1990).
87. Hellstrom-Lindberg, E. et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br. J. Haematol. 120, 1037-1046 (2003).
88. Casadevall, N. et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104, 321-327 (2004).
89. Fontenay-Roupie, M. et al. Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction. Br. J. Haematol. 106, 464-473 (1999). First paper to show the importance of CD95 in mediating the ineffective erythropoiesis of MDS.
90. Hellstrom-Lindberg, E., Kanter-Lewensohn, L. & Ost, A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk. Res. 21, 415-425 (1997).
91. Silva, M. et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J. Biol. Chem. 274, 22165-22169 (1999).
92. Tehranchi, R. et al. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations. Clin. Cancer Res. 11, 6291-6299 (2005).
93. Invernizzi, R. et al. Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes. Leuk. Res. 29, 641-647 (2005).
94. Payvandi, F. et al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-α, IL-1β, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell. Immunol. 230, 81-88 (2004).
95. Raza, A. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc. Res. Tech. 50, 229-235 (2000).
96. Raza, A. et al. Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk. Lymphoma 45, 2099-2104 (2004).
97. List, A. et al. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 352, 549-557 (2005). This paper reports the definitive clinical trial that led to the FDA approval of lenalidomide for MDS.
98. List, A. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355, 1456-1465 (2006).
99. Yoo, C. B. & Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nature Rev. Drug Discov. 5, 37-50 (2006).
100. Silverman, L. R. DNA methyltransferase inhibitors in myelodysplastic syndrome. Best Pract. Res. Clin. Haematol. 17, 585-594 (2004).
101. List, A. F., Vardiman, J., Issa, J. P. & DeWitte, T. M. Myelodysplastic syndromes. Hematology Am. Soc. Hematol. Educ. Program 297-317 (2004).
102. Silverman, L. R. et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20, 2429-2440 (2002).
103. Kantarjian, H. et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106, 1794-803 (2006). References 102 and 103 comprise the definitive clinical trials that led to the FDA approval of two hypomethylating agents for MDS.
104. Kaminskas, E. et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer Res. 11, 3604-3608 (2005).
105. Kantarjian, H. et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109, 52-57 (2007).
106. Kuendgen, A. et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106, 112-119 (2006).
107. Garcia-Manero, G. et al. Phase I/II study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108, 3271-3279 (2006).
108. Gore, S. D. et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 66, 6361-6369 (2006).
109. Wang, H., Chuhjo, T., Yasue, S., Omine, M. & Nakao, S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 100, 3897-3902 (2002).
110. Chen, G. et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 104, 4210-4218 (2004).
111. Rosenfeld, C. & List, A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 14, 2-8 (2000).
112. Greenberg, P. L. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk. Res. 22, 1123-1136 (1998).
113. Greenberg, P. L., Young, N. S. & Gattermann, N. Myelodysplastic syndromes. Hematology Am. Soc. Hematol. Educ. Program 136-161 (2002).
114. Liesveld, J. L., Jordan, C. T. & Phillips, G. L., II. The hematopoietic stem cell in myelodysplasia. Stem Cells 22, 590-599 (2004).